Retatrutide side effects: what the Phase 2 trials actually reported

Retatrutide has produced the largest weight-loss numbers yet reported for a drug — the efficacy side is laid out in our Phase 2 evidence monograph. This page is the other half of that ledger: what the same trials reported about harm. The honest framing first — retatrutide is investigational, still in Phase 3, and everything below comes from two mid-stage trials of a few hundred people each. It is a real drug with a real, dose-related side-effect profile, not a benign peptide.

The dominant signal: gastrointestinal events

Like every incretin-based agent, retatrutide’s most common adverse effects were gastrointestinal. In the 48-week Phase 2 obesity trial, nausea, diarrhea, vomiting and constipation were the most frequently reported events, they were mostly mild to moderate, and they were dose-related — more common at the higher maintenance doses and concentrated during the dose-escalation period.^[1] The parallel Phase 2 trial in adults with type 2 diabetes reported the same pattern: predominantly mild-to-moderate gastrointestinal events that rose with dose.^[2] This is why escalation schedule matters, and it is covered in our dosage page and in the broader GLP-1 GI side-effect timeline.

The glucagon consideration: heart rate

The third receptor is what sets retatrutide apart, and it carries its own signal. In the obesity trial, mean heart rate rose in a dose-dependent way, peaked at around week 24, and then declined toward week 48 — a transient pattern rather than a steady climb.^[1] Glucagon-receptor agonism raising heart rate is mechanistically expected, and it is precisely the kind of cardiometabolic effect that a mid-stage trial can describe but cannot adjudicate for long-term safety.

What we simply don’t know yet

The largest caveat is the absence of long-term data. There are no multi-year exposure results, no cardiovascular or renal outcomes trials, and no post-marketing surveillance — because there is no market. Everything on this page is a Phase 2 read-out. Rare or delayed adverse effects, by definition, do not show up reliably in trials of this size and duration; that is what the ongoing Phase 3 development exists to establish. How retatrutide’s tolerability is likely to compare against the approved dual agonist is discussed in our retatrutide versus tirzepatide comparison — but even there, cross-trial safety comparisons are suggestive, not definitive.

The gray-market problem sits on top of all of this

Because retatrutide is not approved, there is no legitimate supply outside a clinical trial. Anything sold as “research” retatrutide is unregulated, and it adds a second layer of risk that has nothing to do with the molecule’s own adverse events: unknown purity, possible contamination, and unverifiable dosing. The trial data above describe a specific compound given at controlled doses under medical supervision. None of those conditions hold for material bought online, so the Phase 2 safety profile cannot be assumed to transfer to it. This page is not a self-use guide.

The honest bottom line

Retatrutide’s side-effect story is, so far, a familiar incretin one told at a new intensity: dose-related gastrointestinal events as the dominant burden, plus a transient glucagon-linked rise in heart rate.^[1][2] None of that is disqualifying — it is roughly what the class predicts — but the operative words remain investigational and Phase 2. There is no long-term safety record, no approved product, and no safe way to source it outside a trial. The appropriate posture is to watch the Phase 3 data as it arrives and to treat any decision as one for a clinician, not a forum.